P/B
0,8
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
$291M
Market Cap • 10/9/2026
2015
(11 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
28,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
8,2
EPS
—
Market Cap
Market Cap
291M
EV
-24,9M
EV/Revenue
-2,4
EV/EBITDA
0,2
EV/EBIT
0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-12,7%
Total Yield
-12,7%
Payout
0%
Retained Earnings
-381,8M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
847,8%
Capex/Revenue
4,7%
Capex/D&A
194,4%
Capex/OCF
-0,6%
SBC/OCF
—
% PPE
1%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
3
Debt/Equity
0%
Current Ratio
17,2
Quick Ratio
16,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!